Drug intelligence / Profile preview

Poulvac IB Primer

Development stage: Unknown
Lead developer: Zoetis
Modality: Vaccines & Immunotherapeutics
Administration: Oral, Inhalation, Ophthalmic

Overview

**Poulvac IB Primer** is a Zoetis veterinary live-attenuated vaccine for active immunisation of chickens against avian infectious bronchitis caused by Massachusetts-serotype and D274-like infectious bronchitis virus strains. It contains two live attenuated avian infectious bronchitis virus strains, H120 and D274 clone, supplied as a freeze-dried lyophilisate that is reconstituted for spray, eye-drop, or drinking-water administration. Immunity begins 27 days after vaccination and lasts for 16 weeks. ([www2.zoetis.de](https://www2.zoetis.de/content/_assets/Fachinfomationen/Poulvac-IB-Primer_SPC.pdf))

Brand names: Poulvac IB Primer

Targets

SA (Sialic acid)

Beyond the preview

Go deeper on Poulvac IB Primer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poulvac IB Primer.

Explore the full profile